Abstract
Introduction A number of seroprevalence studies in Zambia document the extent of spread of SARS-CoV-2, yet few have examined signs, symptoms and conditions that continue or develop after acute COVID-19 infection (long COVID). This is an important gap given the estimated prevalence of long COVID in other countries. We sought to examine characteristics of post-acute COVID-19 (PAC-19) clinics patients in Zambia and assess factors associated with long COVID at first visit to a PAC-19 clinic and longitudinally among a cohort of patients.
Methods Long COVID was defined, initially in the Zambia PAC-19 clinical guidelines, as new, relapsing, or persistent symptoms lasting >4 weeks after an initial SARS-CoV-2 infection. Severe COVID-19 was defined as COVID-19 episode that required supplemental oxygen therapy, intensive care unit stay or treatment with steroids/remdesivir. We performed a cross-sectional and longitudinal analysis of PAC-19 clinic patients from August 2020 to January 2023 using logistic and mixed effects regression models and considered statistical significance at p<0.05.
Results In total, 1,359 patients attended PAC-19 clinics of whom 548 (40.3%) with ≥2 visits were included in the longitudinal analysis. Patients’ median age was 53 (interquartile range [IQR]: 41-63) years, 919 (67.6%) were hospitalized for acute COVID-19, and of whom 686 (74.6%) had severe COVID-19. Patients with hospital length of stay ≥15 days (adjusted odds ratio [aOR]: 5.37; 95% confidence interval [95% CI]: 2.99-10.0), severe illness (aOR: 3.22; 95% CI: 1.68-6.73), and comorbidities (aOR:1.50; 95% CI: 1.02-2.21) had significantly higher likelihood of long COVID. Longitudinally, long COVID prevalence significantly (p<0.001) declined from 75.4% at the first PAC-19 visit to 26.0% by the fifth visit. The median follow-up time was 7 (IQR: 4-12) weeks.
Conclusion Long COVID symptoms were common among patient presenting for care in PAC-19 clinics in Zambia, but most recovered within ∼2 months. Despite potentially substantial morbidity due to long COVID, few patients overall with COVID-19 attended a PAC-19 clinic. Scaling up PAC-19 services and integrating into routine clinical care could improve access by patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study has been supported in part by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) Grant number/CoAg ID number GH002234. The study sponsor or funder had no role, in the study design collection, analysis, and interpretation of data writing of the report and the decision to submit the article for publication. In addition, there is independence of researchers from funders and all authors, external and internal, had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of University of Zambia Biomedical Research gave waiver for informed consent (Ref No. 2711-2022) for this work. The Zambia National Health Research Authority approved this non-research work (Ref No: NHRA0002/26/05/2022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Included figures, tables and supplementary materials. Addressed reviewers' comments from a journal the paper is under review for publication.
Data Availability
Data are not currently publicly available but may be obtained by a third party. The data are de-identified participant data, available with permission from the Government of the Republic of Zambia (GRZ) – Ministry of Health (MoH), info@moh.gov.zm. A request to access the data can be made to the corresponding author (ykh1@cdc.gov), who will need to get permission from GRZ (MoH) to avail the data. Protocols and statistical analysis information is available as per above.
